https://rectifypharma.com/resource/a-structural-and-mechanistic-model-for-bsep-dysfunction-in-severe-cholestastic-disease-2/ 2024-10-28T17:01:42+00:00 https://rectifypharma.com/resource/a-positive-functional-modulator-of-abcc6-decreases-vascular-calcification-and-improves-kidney-function-in-a-rat-adenine-diet-model/ 2024-11-25T11:47:51+00:00 https://rectifypharma.com/resource/characterization-of-cholestasis-in-a-knock-in-bsepe297g-pfic2-mouse-model/ 2024-11-25T11:49:40+00:00 https://rectifypharma.com/resource/a-class-based-approach-to-drug-discovery-mining-the-pharmacotherapeutic-potential-of-the-abc-transporter-superfamily/ 2024-11-25T11:51:08+00:00 https://rectifypharma.com/resource/a-knock-in-bsepe297g-mouse-presents-with-cholestasis-and-is-a-novel-translational-model-of-pfic2/ 2024-11-25T11:52:46+00:00 https://rectifypharma.com/resource/abc-transporters-human-disease-and-pharmacotherapeutic-potential/ 2024-11-25T11:54:19+00:00 https://rectifypharma.com/resource/identification-and-in-vitro-characterization-of-a-novel-bsep-and-abcb4-dual-acting-positive-functional-modulator-targeting-the-treatment-of-a-broad-range-of-hepatobiliary-diseases/ 2024-11-25T16:24:17+00:00 https://rectifypharma.com/resource/identification-and-in-vitro-characterization-of-novel-abcd1-positive-functional-modulators-for-the-treatment-of-x-linked-adrenoleukodystrophy/ 2024-11-25T16:24:43+00:00 https://rectifypharma.com/resource/abcb4-mdr2-haploinsufficiency-predisposes-mice-to-biliary-injury-and-secondary-cholestasis-and-defines-a-translational-model-of-toxic-bile-induced-hepatobiliary-injury-in-human-cholangiopathy/ 2024-11-26T08:13:57+00:00 https://rectifypharma.com/resource/novel-dual-acting-abcb4-mdr3-and-abcb11-bsep-positive-functional-modulator-demonstrates-anti-cholestatic-and-anti-cholangitis-activity-in-two-orthogonal-models-of-hepatobiliary-disease/ 2025-05-08T17:15:08+00:00 https://rectifypharma.com/resource/a-positive-functional-modulator-of-abcc6-decreases-vascular-calcification-and-improves-kidney-function-in-a-rat-adenine-diet-model-of-chronic-kidney-disease/ 2025-06-05T22:06:44+00:00 https://rectifypharma.com/resource/an-abcb11-variant-registry-and-novel-knockin-mouse-model-of-pfic2-based-on-the-clinically-relevant-abcb11-e297g-variant/ 2025-07-08T15:08:43+00:00 https://rectifypharma.com/resource/rty-406-a-candidate-drug-for-primary-sclerosing-cholangitis-psc-a-dual-acting-abcb4-mdr3-and-abcb11-bsep-positive-functional-modulator-demonstrates-proof-of-mechanism-in-non-human-primates/ 2026-05-22T14:46:55+00:00 https://rectifypharma.com/resource/rty-406-is-a-dual-acting-abcb4-mdr3-and-abcb11-bsep-positive-functional-modulator-that-demonstrates-efficacy-in-a-model-of-primary-sclerosing-cholangitis/ 2026-05-22T14:50:57+00:00 https://rectifypharma.com/resource/abcb4-haploinsufficiency-sensitises-mice-toa-diet-induced-psc-like-hepatobiliary-phenotype-withgallstone-formation/ 2026-05-22T14:54:42+00:00 https://rectifypharma.com/resource/discovery-of-rty-406-a-positive-functional-modulator-of-abcb4-and-bsep-abcb11as-a-disease-modifying-therapyfor-the-treatment-of-primary-sclerosing-cholangiti/ 2026-08-27T08:01:41+00:00